Literature DB >> 19879950

Rapid, flow cytometric assay for NK alloreactivity reveals exceptions to rules governing alloreactivity.

Dianne De Santis1, Bree A Foley, Elisabeth John, David Senitzer, Frank T Christiansen, Campbell S Witt.   

Abstract

Alloreactive NK cells lyse target cells lacking self-HLA-C or the HLA-B-Bw4 epitope. Prior to haploidentical stem cell transplants, donor alloreactivity toward the patient is evaluated by natural killer (NK) cloning followed by testing of the clones in the (51)Cr-release assay. As only a few percent of NK clones are alloreactive, a large number of NK clones must be established and evaluated. This approach is laborious and time consuming, with a complete evaluation taking up to 6 weeks. We developed a flow cytometry-based cytotoxicity assay utilizing CD107a expression on 12-day polyclonally expanded NK cells and showed that NK alloreactivity mediated by inhibitory and activating KIR can be detected by measuring CD107a expression following incubation with targets lacking the appropriate class I epitope. The percentage of alloreactive NK cells varied greatly between individuals and was easily estimated by the CD107a assay. For each epitope (C1, C2, Bw4), donors were found who did not have alloreactivity, although alloreactivity was predicted by the current rules thought to govern alloreactivity. The data emphasize the importance of demonstrating alloreactivity in a functional assay. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19879950     DOI: 10.1016/j.bbmt.2009.10.026

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  3 in total

1.  Molecular determinant-based typing of KIR alleles and KIR ligands.

Authors:  Rafijul Bari; Matthias Leung; Victoria E Turner; Christy Embrey; Barbara Rooney; Martha Holladay; Wing Leung
Journal:  Clin Immunol       Date:  2011-01-15       Impact factor: 3.969

2.  Human AdV-specific T cells: persisting in vitro functionality despite lethal irradiation.

Authors:  R Geyeregger; C Freimüller; J Stemberger; G Fischer; V Witt; G Fritsch
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

Review 3.  The More, The Better: "Do the Right Thing" For Natural Killer Immunotherapy in Acute Myeloid Leukemia.

Authors:  Sarah Parisi; Mariangela Lecciso; Darina Ocadlikova; Valentina Salvestrini; Marilena Ciciarello; Dorian Forte; Giulia Corradi; Michele Cavo; Antonio Curti
Journal:  Front Immunol       Date:  2017-10-19       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.